Plus Therapeutics Concludes Enrolment In Initial-Stage Study Of Cerebrospinal Fluid Cancer Setting

Plus Therapeutics PSTV has concluded patient enrolment in the first cohort of the ReSPECT-LM Phase 1/2a dose escalation clinical trial of Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases (LM).

The company is planning to provide enrolment and complete clinical updates in the third quarter of 2022.

Norman LaFrance, M.D., Chief Medical Officer and SVP, commented : “We are pleased with initial response to the ReSPECT-LM trial by patients and physicians and the very early promising drug performance, Patients seemed to tolerate 186RNL infusions and the drug circulated completely and rapidly throughout the cebrebrospinal fluid space.”

The company said that the Data Safety & Monitoring Board (DSMB) will take a decision on further dose escalation.

Leptomeningeal metastases is a rare complication of cancer in which the disease spreads to the membranes (meninges) surrounding the brain and spinal cord.

The U.S. FDA granted Fast Track designation to 186RNL for the treatment of leptomeningeal metastases (LM) in the month of November 2021.

Plus Therapeutics Shares are trading high at $0.56 in the regular trading session.

Posted In: Patient EnrolmentBiotechPenny StocksHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.